Table 1.

Baseline demographics and disease characteristics

	Cohorts by PD-L1 expression						All patients (n = 146)
	< 1% (n = 74)	≥ 1–< 25% (n = 31)	≥ 25–< 50% (n = 11)	≥ 50%
				Total (n = 30)	EGFR − (n = 25)	EGFR + (n = 5)
Age, median years (range)	62 (35–74)	61 (38–74)	64 (46–76)	59 (40–74)	59 (40–74)	57 (41–66)	62 (35–76)
Male	58 (78.4)	24 (77.4)	10 (90.9)	23 (76.7)	20 (80.0)	3 (60.0)	115 (78.8)
ECOG performance status
0	5 (6.8)	1 (3.2)	0	2 (6.7)	2 (8.0)	0	8 (5.5)
1	69 (93.2)	30 (96.8)	11 (100)	28 (93.3)	23 (92.0)	5 (100)	138 (94.5)
Tumor histology
Adenocarcinoma	43 (58.1)	18 (58.1)	3 (27.3)	14 (46.7)	9 (36.0)	5 (100)	78 (53.4)
Squamous cell carcinoma	30 (40.5)	13 (41.9)	7 (63.6)	16 (53.3)	16 (64.0)	0	66 (45.2)
Others	1 (1.4)	0	1 (9.1)	0	0	0	2 (1.4)
Disease stage
IIIa	1 (1.4)	0	0	0	0	0	1 (0.7)
IIIb	8 (10.8)	4 (12.9)	1 (9.1)	1 (3.3)	0	1 (20.0)	14 (9.6)
IV	65 (87.8)	27 (87.1)	10 (90.9)	29 (96.7)	25 (100)	4 (80.0)	131 (89.7)
Metastases	74 (100)	31 (100)	11 (100)	30 (100)	25 (100)	5 (100)	146 (100)
Number of metastatic organs
≤ 2	53 (71.6)	22 (71.0)	8 (72.7)	23 (76.7)	20 (80.0)	3 (60.0)	106 (72.6)
> 2	21 (28.4)	9 (29.0)	3 (27.3)	7 (23.3)	5 (20.0)	2 (40.0)	40 (27.4)
Previous therapies
Surgery	28 (37.8)	15 (48.4)	4 (36.4)	10 (33.3)	8 (32.0)	2 (40.0)	57 (39.0)
Chemotherapy	71 (95.9)	30 (96.8)	11 (100)	30 (100)	25 (100)	5 (100)	142 (97.3)
Radiotherapy	26 (35.1)	12 (38.7)	4 (36.4)	6 (20.0)	5 (20.0)	1 (20.0)	48 (32.9)
Adjuvant therapy	9 (12.2)	5 (16.1)	0	2 (6.7)	2 (8.0)	0	16 (11.0)
Neoadjuvant therapy	2 (2.7)	0	0	0	0	0	2 (1.4)

Data are presented in n (%), unless otherwise specified